MRNA vs BNTX

For growth investors, BioNTech SE (BNTX) is the stronger pick with 0.

2% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Analysts rate BioNTech SE (BNTX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BioNTech SE (BNTX) delivered a total return of -42.

8%, compared to -71. 3% for Moderna, Inc. (MRNA). Over 10 years, the gap is even starker: BNTX returned +585. 5% versus MRNA's +151. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioNTech SE (BNTX) is the lower-risk stock at 1.

14β versus Moderna, Inc. 's 1. 82β — meaning MRNA is approximately 59% more volatile than BNTX relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 22% for Moderna, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioNTech SE (BNTX) is pulling ahead at 0.

2% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Moderna, Inc. grew EPS 21. 7% year-over-year, compared to -62. 8% for BioNTech SE. Over a 3-year CAGR, BNTX leads at -45. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioNTech SE (BNTX) is the more profitable company, earning -39.

6% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps -39. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BNTX leads at -22. 6% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — BNTX leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioNTech SE (BNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

14), +585. 5% 10Y return). Moderna, Inc. (MRNA) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BNTX: +585. 5%, MRNA: +151. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.